Free shipping on all orders over $ 500

Dabigatran etexilate mesylate

Cat. No. M3759

All AbMole products are for research use only, cannot be used for human consumption.

Dabigatran etexilate mesylate Structure
Synonym:

BIBR 1048MS

Size Price Availability Quantity
5mg USD 50  USD50 In stock
10mg USD 70  USD70 In stock
50mg USD 105  USD105 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Dabigatran etexilate may provide a promising alternative for the treatment of postprocedural vision loss after ppv. A direct thrombin inhibitor, dabigatran etexilate (hereinafter referred to as dabigatran) was approved in the Russian Federation for prevention of thromboembolic complications in orthopaedic practice (2009), for prevention of ischaemic embologenic stroke in atrial fibrillation (2011) and for treatment of recurrent thrombosis of deep veins and pulmonary artery thromboembolism (2014). Additional administration of 2 × 110 mg dabigatran etexilate (Pradaxa(®)), a novel direct thrombin inhibitor, resulted in a prompt and marked improvement of visual acuity, which indicated improved blood flow in the central vessels of the optic nerve. Dabigatran etexilate appeared to have several pharmacokinetic and pharmacodynamic advantages over warfarin, as well as a favorable efficacy and safety profile being at least noninferior and often superior to warfarin in patients with non-valvular AF. The latter was shown in the clinical trials, meta-analyses and studies with 'real-world' data. Currently ongoing trials will expand the body of evidence on warfarin and will aid decision making in currently controversial areas. Important limitations of dabigatran etexilate include contraindications for its use in patients with prosthetic heart valves and end-stage chronic kidney disease.

Chemical Information
Molecular Weight 723.84
Formula C35H45N7O8S
CAS Number 872728-81-9
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Beliavskaia OO, et al. Angiol Sosud Khir. Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor.

[2] Dzeshka MS, et al. Expert Opin Drug Saf. Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.

[3] Schönfeld CL, et al. Case Rep Ophthalmol. Recovery of visual function after administration of dabigatran etexilate.

Related Thrombopoietin/Thrombin Products
Melagatran

Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin.

Idraparinux sodium

Idraparinux sodium (SANORG 34006) is a long-acting indirect factor Xa inhibitor.

Desirudin

Desirudin is a thrombin inhibitor that inhibits thrombosis and venous stasis thrombosis.Desirudin can be used in studies related to thrombocytopenia or platelet dysfunction.

TP508

TP508 is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule.

Succinyl-(Pro58, D-Glu65)-Hirudin (56-65) (sulfated)

Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a KD < 100 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Dabigatran etexilate mesylate, BIBR 1048MS supplier, Thrombopoietin/Thrombin, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.